Top

World Journal of Pediatrics

Published in:

01-06-2018 | Original Article

Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants

Authors: Giovanni Frongia, Ji-Oun Byeon, Raoul Arnold, Arianeb Mehrabi, Patrick Günther

Published in: World Journal of Pediatrics | Issue 3/2018

Abstract

Background

The indication and extent of cardiac screening before oral propranolol therapy (OPT) in patients with infantile hemangioma (IH) has been challenged. In this study, we evaluated pre-OPT cardiac diagnostics in a pediatric IH cohort in our department.

Methods

Retrospective chart review of infants ≤ 12 months old with IH undergoing OPT. The diagnostics prior to OPT, occurrence of complications, and outcome were recorded.

Results

A total of 234 patients were evaluated. The mean age at the onset of OPT was 4.2 ± 0.3 months, the average duration of OPT was 6.1 ± 0.1 months, and the average follow-up was 12.3 ± 0.7 months. Echocardiograms and electrocardiograms were performed prior to OPT in all patients. One hundred and three (44.0%) echocardiograms revealed pathological findings, 19 (8.1%) of which were minor (including atrial septal defects, pulmonary stenosis, and patent ductus arteriosus). Pathological findings were observed in 17 (7.3%) of electrocardiograms, only one (0.4%) of which was minor (suspected cardiac arrhythmia, subsequently excluded by long-term electrocardiogram analysis). These findings did not contraindicate OPT and no severe adverse events associated with OPT occurred during the follow-up period.

Conclusions

Routine cardiac screening by electrocardiogram and echocardiogram before OPT is debatable and not routinely indicated in children with IH. Further studies are necessary to draw definite conclusions on the reasonable indication and extent of this diagnostic approach.

Hemangioma Investigator Group, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150:291–4.CrossRef

Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341:173–81.CrossRefPubMed

Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.CrossRefPubMed

Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthetic Surg. 2011;64:445–51.CrossRef

Fuchsmann C, Quintal MC, Giguere C, Ayari-Khalfallah S, Guibaud L, Powell J, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg. 2011;137:471–8.CrossRefPubMed

Schupp CJ, Kleber JB, Günther P, Holland-Cunz S. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol. 2011;28:640–4.CrossRefPubMed

Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, Bodak N, Hamel-Teillac D, Kupfer-Bessaguet I, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol. 2011;64:827–32.CrossRefPubMed

Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128:e259–66.CrossRefPubMed

Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013;30:182–91.CrossRefPubMed

10.

Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735–46.CrossRefPubMed

11.

Price CJ, Lattouf C, Baum B, McLeod M, Schachner L, Duarte AM, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011;147:1371–6.CrossRefPubMed

12.

Kallen RJ, Mohler JH, Lin HL. Hypoglycemia: a complication of treatment of hypertension with propranolol. Clin Pediatr (Phila). 1980;19:567–8.CrossRef

13.

Tomlinson B, Cronin CJ, Graham BR, Prichard BN. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. J Cardiovasc Pharmacol. 1987;10(Suppl 11):S69–75.CrossRefPubMed

14.

Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610–4.CrossRefPubMed

15.

Blei F, McElhinney DB, Guarini A, Presti S. Cardiac screening in infants with infantile hemangiomas before propranolol treatment. Pediatr Dermatol. 2014;31:465–70.CrossRefPubMed

16.

Raphael MF, Breugem CC, Vlasveld FA, de Graaf M, Slieker MG, Pasmans SG, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study. J Am Acad Dermatol. 2015;72:465–72.CrossRefPubMed

17.

Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128–40.CrossRefPubMedPubMedCentral

18.

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.CrossRefPubMed

19.

Pickoff AS, Zies L, Ferrer PL, Tamer D, Wolff G, Garcia O, et al. High-dose propranolol therapy in the management of supraventricular tachycardia. J Pediatr. 1979;94:144–6.CrossRefPubMed

20.

Artman M, Grayson M, Boerth RC. Propranolol in children: safety-toxicity. Pediatrics. 1982;70:30–1.PubMed

21.

Baron PW, Barrow RE, Pierre EJ, Herndon DN. Prolonged use of propranolol safely decreases cardiac work in burned children. J Burn Care Rehabil. 1997;18:223–7.CrossRefPubMed

22.

Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124:e423–31.CrossRefPubMed

23.

Buckmiller LM, Munson PD, Dyamenahalli U, Dai Z, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 2010;120:676–81.CrossRefPubMed

24.

Manunza F, Syed S, Laguda B, Linward J, Kennedy H, Gholam K, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162:466–8.CrossRefPubMed

25.

Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 2011;64:292–9.CrossRefPubMed

26.

McBride JT, McBride MC, Viles PH. Hypoglycemia associated with propranolol. Pediatrics. 1973;51:1085–7.PubMed

27.

Horev A, Haim A, Zvulunov A. Propranolol induced hypoglycemia. Pediatr Endocrinol Rev. 2015;12:308–10.PubMed

28.

Dyme JL, Thampan A, Han EJ, Nyirenda TL, Kotb ME, Shin HT. Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. Cardiol Young. 2012;22:424–9.CrossRefPubMed

29.

Techasatian L, Komwilaisak P, Panombualert S, Uppala R, Jetsrisuparb C. Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. Acta Paediatr. 2016;105:e257–62.CrossRefPubMed

30.

Cushing SL, Boucek RJ, Manning SC, Sidbury R, Perkins JA. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg. 2011;144:78–84.CrossRefPubMed

31.

McSwiney E, Murray D, Murphy M. Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure. Eur J Pediatr. 2014;173:63–8.CrossRefPubMed

32.

Patel NJ, Bauman NM. How should propranolol be initiated for infantile hemangiomas: inpatient versus outpatient? Laryngoscope. 2014;124:1279–81.CrossRefPubMed

33.

Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health. 2012;48:902–6.CrossRefPubMed

34.

Solman L, Murabit A, Gnarra M, Harper JI, Syed SB, Glover M. Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. Arch Dis Child. 2014;99:1132–6.CrossRefPubMed

35.

Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics. 2001;107:E32.CrossRefPubMed

36.

Shuler CO, Black GB, Jerrell JM. Population-based treated prevalence of congenital heart disease in a pediatric cohort. Pediatr Cardiol. 2013;34:606–11.CrossRefPubMed

37.

Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol. 1995;16:103–13.CrossRefPubMed

38.

Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890–900.CrossRefPubMed

39.

Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171–9.CrossRefPubMed

40.

El Ezzi O, Hohlfeld J, de Buys Roessingh A. Propranolol in infantile haemangioma: simplifying pretreatment monitoring. Swiss Med Wkly. 2014;144:w13943.PubMed

41.

Liu LS, Sokoloff D, Antaya RJ. Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas—is it indicated? Pediatr Dermatol. 2013;30:554–60.CrossRefPubMed

Title: Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants
Authors: Giovanni Frongia
Ji-Oun Byeon
Raoul Arnold
Arianeb Mehrabi
Patrick Günther
Publication date: 01-06-2018
Publisher: Childrens Hospital, Zhejiang University School of Medicine
Published in: World Journal of Pediatrics / Issue 3/2018
Print ISSN: 1708-8569
Electronic ISSN: 1867-0687
DOI: https://doi.org/10.1007/s12519-018-0137-7

At a glance: The STEP trials

Springer Medicine

Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Mental health of the male adolescent and young man: the Copenhagen statement

Serum proteomic profiling for autism using magnetic bead-assisted matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a pilot study

Morbidity and mortality of coagulase-negative staphylococcal sepsis in very-low-birth-weight infants

Clinical characteristics of two cohorts of infantile spasms: response to pyridoxine or topiramate monotherapy

Are therapeutic diets an emerging additional choice in autism spectrum disorder management?

Two novel mutations in the GAN gene causing giant axonal neuropathy